
ChromaDex Corp (NAGE) Stock Forecast & Price Target
ChromaDex Corp (NAGE) Analyst Ratings
Bulls say
Niagen Bioscience is expected to see a boost in its financial performance in the coming quarters thanks to the launch of Niagen Plus, its clinician-directed telehealth platform, which allows patients to access prescription-only Niagen from home. This program, along with the potential introduction of a pen-like autoinjector and the recent establishment of a United States Pharmacopeia monograph for Niagen, could further accelerate the company's commercial uptake in a lucrative and rapidly growing market segment. Additionally, the recent lawsuit against regulators and potential future removal of competing NMN-based products could benefit Niagen Bioscience's sales ramp, while its strong financial profile with no debt and expanding EBITDA margins provide further support for a positive outlook.
Bears say
Niagen Bioscience is heavily reliant on the success and reputation of their flagship product, TruNiagen, and the supplements industry is highly competitive with larger and more established brands. Additionally, changes in government regulations and potential stock dilution risks could also impact the company's performance and shareholder value. Overall, these factors make the outlook for Niagen Bioscience's stock uncertain and potentially risky from a financial analyst's perspective.
This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.
ChromaDex Corp (NAGE) Analyst Forecast & Price Prediction
Start investing in ChromaDex Corp (NAGE)
Order type
Buy in
Order amount
Est. shares
0 shares